Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.63 |
| ▸ | LMNA | P02545 | 5/20 | 0.63 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.62 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.62 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.62 |
| ▸ | GSR | P00390 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | MAOB | P27338 | 3/20 | 0.57 |
| ▸ | NPC1 | O15118 | 3/20 | 0.57 |
| ▸ | RAB9A | P51151 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | IAPP | P10997 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1447675 | 1.00 | MAPT (0.63) | MAPTLMNAHDAC1HDAC8HDAC6 | |
| SCHEMBL31356685 | 1.00 | MAPT (0.63) | MAPTLMNAHDAC1HDAC8HDAC6 | |
| SCHEMBL14441077 | 0.85 | MAPT (0.76) | MAPTLMNAHDAC1HDAC8HDAC6 | |
| SCHEMBL31553473 | 0.83 | GSR (0.79) | MAPTLMNAHDAC1HDAC8HDAC6 | |
| SCHEMBL22596712 | 0.83 | HDAC1 (0.67) | MAPTLMNAHDAC1HDAC8HDAC6 | |
| SCHEMBL2744240 | 0.83 | GSR (0.79) | MAPTLMNAHDAC1HDAC8HDAC6 | |
| SCHEMBL30468232 | 0.83 | GSR (0.79) | MAPTLMNAHDAC1HDAC8HDAC6 | |
| SCHEMBL2744242 | 0.83 | GSR (0.79) | MAPTLMNAHDAC1HDAC8HDAC6 | |
| SCHEMBL1404763 | 0.83 | IAPP (0.69) | MAPTLMNAHDAC1HDAC8HDAC6 | |
| SCHEMBL1404762 | 0.83 | IAPP (0.69) | MAPTLMNAHDAC1HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4643805-A | CONTAINING UNSATURATED OXO PYRIDINE, AROMATIC, FURAN, OR THIOPHENE COMPOUND | POPESCU FRANCINE (FR) | 1987-02-17 | — | — | US | claimed |
| EP-3930849-B1 | THIAZOLE DERIVATIVES AS PROTEIN SECRETION INHIBITORS | KEZAR LIFE SCIENCES (US) | 2025-02-19 | — | — | EP | disclosed |
| US-20220153732-A1 | PROTEIN SECRETION INHIBITORS | ENODIA THERAPEUTICS SAS (FR) | 2022-05-19 | — | — | US | disclosed |
| EP-3297986-B1 | BETA NAPHTHOLETHER SULFONATES, METHOD FOR THEIR PREPARATION AND THEIR USE AS GLOSS IMPROVERS | BASF SE (DE) | 2019-07-10 | — | — | EP | disclosed |
| WO-2015101928-A1 | FUSED THIOPHENE AND THIAZOLE DERIVATIVES AS ROR GAMMA MODULATORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2015-07-09 | — | — | WO | disclosed |
| WO-2015101928-A1 | FUSED THIOPHENE AND THIAZOLE DERIVATIVES AS ROR GAMMA MODULATORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2015-07-09 | — | — | WO | disclosed |
| WO-2011035355-A1 | NOVEL ANTIMALARIAL 3-AZABICYCLO[3.2.2]NONANE DERIVATIVES | UNIVERSITY OF GRAZ (AT) | 2011-03-31 | — | — | WO | disclosed |
| EP-2301627-A1 | Novel antimalarial 3-azabicyclo[3.2.2]nonane derivatives | University of Graz (AT) | 2011-03-30 | — | — | EP | disclosed |
| US-7291743-B2 | Isoxazole derivatives and methods of treating nitric oxide mediated diseases | GENEBLUE CORPORATION (US) | 2007-11-06 | — | — | US | disclosed |
| EP-0936213-B1 | Unsaturated oxime ethers and their use as fungicides and insecticides | DOW AGROSCIENCES LLC (US) | 2003-03-26 | — | — | EP | disclosed |
| US-6369110-B1 | PROPHYLACTIC AGENT FOR DISEASES CAUSED BY THE ACCELERATION OF THE SODIUM/PROTON EXCHANGE TRANSPORT SYSTEM | SUMITOMO PHARMACEUTICALS COMPANY (JP) | 2002-04-09 | — | — | US | disclosed |
| EP-1083166-A1 | NOVEL SUBSTITUTED GUANIDINE DERIVATIVES AND PROCESS FOR PRODUCING THE SAME | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2001-03-14 | — | — | EP | disclosed |
| US-6177462-B1 | Unsaturated oxime ethers and their use as fungicides and insecticides | ROHM AND HAAS COMPANY | 2001-01-23 | — | — | US | disclosed |
| EP-0936213-A1 | Unsaturated oxime ethers and their use as fungicides and insecticides | ROHM AND HAAS COMPANY (US) | 1999-08-18 | — | — | EP | disclosed |
| US-4288456-A | Compositions containing 1-aryl-5-(2-propenylamino)-1-penten-3-ones and method for treating inflammatory conditions | E. R. SQUIBB & SONS, INC. (US) | 1981-09-08 | — | — | US | disclosed |
| US-4173649-A | ANTIULCER AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1979-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220153732-A1 | PROTEIN SECRETION INHIBITORS | SEC61B, SEC61A1, SEC61G | MAPT 2487/4885LMNA 3715/4885HDAC1 4243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.